Hospital

BIIB080 is designed to target microtubule-associated protein tau mRNA, aimed to reduce the production of tau protein.

CAV-1 is a key protein in lipid rafts that helps control cellular processes such as growth, survival, and migration.

Pharmacists can address micronutrient deficiencies, aiding those with type 2 diabetes as they face a higher risk.

Siremadlin is a novel, investigational, second-generation antagonist that binds to MDM2.

Tocilizumab-bavi received FDA approval in September 2023 as the first biosimilar to tocilizumab for the treatment of various adult and pediatric arthritis conditions.

Generics play a crucial role in mitigating drug shortages by offering a real alternative for 80% of drugs that are becoming increasingly unavailable in Italy.

The predictive tool may reveal the mechanisms underlying treatment resistance in patients with HER+ breast cancer.

Positive results from an interim analysis of the phase 3 ALIGN study bolstered atrasentan towards receiving accelerated approval for patients with immunoglobulin A nephropathy, a rare condition that can cause kidney failure.

Real-time profiling of T-cell activation states in non-CAR T-cells may help guide treatment decisions.

Pharmacists play a crucial role in educating patients on proper administration and adherence to GLP-1 treatments.

By decade’s end, approval of additional bispecifics is expected for hematological malignancies, solid tumors, and non-oncology conditions such as inflammatory, autoimmune, neurodegenerative and vascular diseases, and ocular disorders and infections.

The registry data showed that cardiac magnetic resonance (CMR) was obtained in more clinically complex patients with recurrent pericarditis.

The Auto-Pure 2400 system combines liquid handling and magnetic cell isolation for efficient latent tuberculosis testing.

Pharmacists performed weekly toxicity and tumor lysis syndrome monitoring.

Current recommended levels of vitamin B12 might not be sufficient to protect against neurological decline.

Sarah Spinler, PharmD, FCCP, FAHA, FASHP, AACC, discussed management of atrial fibrillation in patients with cancer.

Host Craig Beavers spoke with several presenters, researchers, and experts about the key data being discussed at the meeting.

Given rituximab’s tendency to cause infections in patients being treated for autoimmune diseases, the addition of intravenous immunoglobulin works to reduce that risk and induce clinical improvements.

Jawad Butt, MD, offers insight into his analysis of the FINEARTS-HF trial.

Patients in the treatment group had a 21% lower risk of cardiovascular death or first heart failure hospitalization overall, but the between-group difference did not meet the threshold for statistical significance for this primary end point.

The trial is the first to test the cardiovascular benefits of an oral glucagon-like peptide-1 (GLP-1) agonist.

The DapaTAVI study is the first trial of a sodium-glucose cotransporter-2 (SGLT2) inhibitor for valvular disease.

The availability of this option could make physicians more comfortable when prescribing ticagrelor, which could help solve the challenge of undertreatment with antiplatelet therapy.

Rivaroxaban offers more predictable dosing, eliminates frequent blood tests, and is less likely to interact with foods.

The results should lead to a guideline update recommending extended treatment with a reduced-dose anticoagulant in this patient population.

The STRIDE trial was first of its kind to evaluate the use of a GLP-1 agonist in PAD management.

Vitamin E intake, specifically α-tocopherol, may reduce the development of peanut allergies and anaphylaxis in newborns.

Colorectal cancer cases are on the rise—here is everything you need to know as an oncology pharmacist.

In certain patients with chronic kidney disease (CKD), peritoneal dialysis maintained hemodynamic stability, optimal nutritional status, reduced hospitalization, and lowered diuretics reliance.

Results support a 2020 meta-analysis showing that older adults with chronic pain are nearly twice as likely to develop frailty compared to those without chronic pain.